- authorisedTherapeutic confirmatory (Phase III)
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Obesity or Overweight With at Least One Weight Related Comorbidity Without Type 2 Diabetes Mellitus
This clinical trial is testing a new medicine called AZD6234 for adults who are overweight or living with obesity. Researchers want to see if the drug helps people lose weight safely over 68 weeks, compared with a dummy treatment, in people who do not have type 2 diabetes.
Italy · Czechia · Germany - recruitingPHASE3
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
This study is testing a new medicine called AZD6234 for adults who are overweight or have obesity and other health issues, including some with type 2 diabetes. It aims to see if adding AZD6234 to their current weight management medicines helps them lose more weight safely.
United States · Argentina · Brazil